David Diemert
Infectious Disease · Washington, DCNPI 1659388262
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,878 of the $8,070 with a category attached, or 97.6%. Merck accounts for 77.8% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $3,885, 2.8 times the $1,395 reported in 2022.
Across 8 payments — averaging $1008.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6K
- Pfizer$2K
Across 126 payments — averaging $17,859 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$1.2M
- Pfizer$811K
- Regeneron$239K
What the payments were for
- Consulting fees$7,87898%
- Travel & lodging$1932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,070 in reported general payments places this provider in the 85th percentile of 74 infectious disease providers in District of Columbia.
See all infectious disease providers in District of Columbia →
Other infectious disease in Washington
- Jesse GoodmanWashington$1.8M
- Theo HodgeWashington$1M
- Robert GasserWashington$922K
- Princy KumarWashington$270K
- Jose ChavezWashington$254K
- Linda NabhaWashington$60K
- Gebeyehu TeferiWashington$25K
- Jose BordonWashington$12K
- Rebecca KumarWashington$12K
- Jeffrey MurrayWashington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.